MG-132

製品コードS2619

MG-132化学構造

分子量(MW):475.62

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

サイズ 価格(税別)  
JPY 10300
JPY 30200
JPY 80000
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

Selleckは効果が一番いいである(S,R,S)-(-)-2のコンフィギュレーションを採用しましたので、MG-132プロテアソームの抑制効果はSigmaの同類製品の効果より著しく高くなります

正常には、p21蛋白はユビキチン化で分解されますが、MG-132はプロテアソームの活性を抑制することを通じて、p21蛋白の貯まりを引き起こします。だから、MG-132の抑制効果は強ければ強いほど、p21蛋白の貯まりは多くなってきます。(検査された蛋白:p21  細胞株:HeLa细胞株 処理条件:濃度5μM 処理時間:6h)

文献中Selleckの製品使用例(165)

質量管理及び製品安全説明書

Proteasome阻害剤の選択性比較

生物活性

製品説明 MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.
ターゲット
20S proteasome [9]
(Cell-free assay)
100 nM
体外試験

MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LPS-stimulated RAW264.7 cells NGnlflFHfW6ldHnvckBCe3OjeR?= MYeyOUDPxE1? M3zBOWROW09? NEjoUmZKdmirYnn0d{BvcXS{aXOgc5hq\GVicILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOC5zIN88US=> M33JfFI1Pjl5NEm2
HL-60 MVfDfZRwfG:6aXOgRZN{[Xl? MmrXOFAh|ryP M{fmVVQ5KGh? NIq3TmhFVVOR NHn2U|RKSzVyPEGwJO69VQ>? MUeyOFY6PzR7Nh?=
SMMC-7721 MlKyR5l1d3SxeHnjJGF{e2G7 MYG0NEDPxE1? NWHjWFh[PDhiaB?= MVnEUXNQ NGDpd|FKSzVyPUeuNUDPxE1? NEnoeWEzPDZ7N{S5Oi=>
A-549 NUHkbFZxS3m2b4TvfIlkKEG|c3H5 MVy0NEDPxE1? Mm\qOFghcA>? NXfKZXZMTE2VTx?= MkeyTWM2ODxzMDFOwG0> MVWyOFY6PzR7Nh?=
MCF-7 M1G4c2N6fG:2b4jpZ{BCe3OjeR?= MWe0NEDPxE1? NFjORnQ1QCCq NGjyXoZFVVOR NVfmdVUxUUN3ME23MlMh|ryP MUOyOFY6PzR7Nh?=
SW-480 MmnqR5l1d3SxeHnjJGF{e2G7 NVSxPXNXPDBizszN NEDzTJA1QCCq M{DWXmROW09? MYLJR|UxRTRizszN MonHNlQ3QTd2OU[=
NCI-H929 NGf0e4pEgXSxdH;4bYMhSXO|YYm= NGTRbGgyKM7:TR?= MVK3NkBp MYDEUXNQ NXnS[GJWUUN3ME2wMlE4KM7:TR?= NYnSSWhKOjR4MkWwPFg>
293T M3riTmN6fG:2b4jpZ{BCe3OjeR?= NV64W202OTBizszN NVy4RoV{PzJiaB?= MWHEUXNQ NV3EOJRnUUN3MEyyJO69VQ>? NXLzTIdHOjR4MkWwPFg>
293T M1LvXmZ2dmO2aX;uJGF{e2G7 NIno[JkyOCEQvF2= NVvVSGV7OjRiaB?= NHy2cZlFVVOR MYTNc4RmemG2ZXz5JIlv\HWlZYOgbIVifC2|aH;jb{Ah NFzVXmkzPDZ{NUC4PC=>
HeLa Mn;1T4lv[XOnIFHzd4F6 M1PzZVExKM7:TR?= MUSxJIg> MYrEUXNQ NEnac|VKdmS3Y3XzJHBCWlBiY3zlZZZi\2ViYomgbY5pcWKrdHnu[{Bxem:|ZXHzc41mKGGldHn2bZR6 NVvRZVM4OjR|MkG4N|M>
MDA-MB-231 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWexJO69VQ>? MYO3NkBp MUHEUXNQ M{i0TWlEPTB;MD6xPEDPxE1? NIXOVYUzPDF3M{KwOi=>
MCF-7 M4T6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfwfZAyKM7:TR?= MWG3NkBp NVmzN5ZSTE2VTx?= Mlr6TWM2OD1yLkGzJO69VQ>? Mmf4NlQyPTN{ME[=
MCF10A MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHVcmwyKM7:TR?= M3TybFczKGh? MljxSG1UVw>? NFLuOmlKSzVyPUCuNlkh|ryP M1GzVVI1OTV|MkC2
HEK-293 MnnuT4lv[XOnIFHzd4F6 MofGNkBidmRiMkCg{txO M4nNOlIhcA>? MYnEUXNQ NF7wRYVKdmirYnn0d{BEcFRvTDDhZ5Rqfmm2eTD3bZRpKEmFNUCgc4YhQSCwTTC= MWqyN|U1ODd7MB?=
Calu6 MX3GeY5kfGmxbjDBd5NigQ>? M1POZlExKM7:TR?= MX2xPEBp NV6zfHlVTE2VTx?= NYjRWmZ7W2mpbnnmbYNidnSueTDhZ4N2dXWuYYTld{BnemG2YYjpckBxemWldYLzc5I> M4G4SFI{PTB4NEi2
IFN-gamma-induced RAW264.7 M1XISWZ2dmO2aX;uJGF{e2G7 NX7veFRYTE2VTx?= NULjcXM6UW6qaXLpeJMhdmm2cnnjJI95cWSnIIDyc4R2[3Srb36ge4l1cCCLQ{WwJI9nKDBwMEe3JO69VQ>? M2C4UVIzOjd5Mke3
IPC227F MlG0R5l1d3SxeHnjJGF{e2G7 NHTWclMyKM7:TR?= M1G1elQ5KGh? NVrnS2p6TE2VTx?= M1zSSWlEPTB;MD6wO|ch|ryP NEH6RoEzOTl{NEWyPC=>
Hepa-1c1c7 MlSySpVv[3Srb36gRZN{[Xl? MVeyOUDPxE1? NH;WTIE3KGh? M1rMTmROW09? NV\yZ3VtUW6lcnXhd4V{KE6{ZkKgdJJwfGWrbjDs[ZZmdA>? MWqyNFM6OjV2NB?=
COS-7 NVT1b3dYS3m2b4TvfIlkKEG|c3H5 MYmxNEDPxE1? NHfmcoZFVVOR MlG5TWM2ODxzMDFOwG0> M1;MUFE5ODh6MEm3
HuH-7 MVrDfZRwfG:6aXOgRZN{[Xl? M1G1U|ExKM7:TR?= MWPEUXNQ NE\P[WpKSzVyPEGwJO69VQ>? NFy1b|YyQDB6OEC5Oy=>
OCI-Ly3 MoXFSpVv[3Srb36gRZN{[Xl? NULxRohQOTBizszNxsA> M{nsUlQhcA>? NUHpWVBGTE2VTx?= NHHZNItKdmS3Y3XzJIh2dWGwIFnrZZBx[UKjbIDoZUB{fGGkaXzpfoF1cW:wIIfpeIghTUN3MDDv[kAyKM7:TR?= MUexPFAzPDFzMx?=
A2780 cDDP NH\mPHZCeG:ydH;zbZMhSXO|YYm= NX;kUG9lOjRiaB?= NYPYNlliTE2VTx?= NHrReXJKdmS3Y3XzJIFxd3C2b4Ppd{BjgSCrbnjpZol1cW6pIGDUSW4h\GWpcnHkZZRqd25? NWHO[pAxOTd4OESwNVg>
LPS-stimulated RAW264.7 cells MXrGeY5kfGmxbjDBd5NigQ>? M{W4UWROW09? MWnJcohq[mm2czDOSk1s[XCyYVKgSG5CKGKrbnTpcoc> NIfZVIgyPzRyN{K3Oy=>
PC12 NFHkV4xHfW6ldHnvckBCe3OjeR?= MlfMNVAxKM7:TdMg M3XhTlI1KGh? NI[1e3lFVVOR MWrJcohq[mm2czC2MW9JTEFvIHHu[EBJOk9{LXnu[JVk\WRiY4n0c5RwgGmlaYT5 Mn;LNVcyPTh2NUS=
PC3 NUHv[m1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXeyNEDPxE1? M3;GNVQ5KGh? M2L6[GROW09? M4\Zd2lEPTB;MD62JO69VQ>? M3rhelE3Pjh4NUO3
LP-1 M4fRV2Fxd3C2b4Ppd{BCe3OjeR?= MkLNN|AxKG6P NWHX[WNsOjRiaB?= MY\EUXNQ MX\JcoR2[2W|IHHwc5B1d3OrczDifUBqdmO{ZXHzbY5oKGOuZXH2[YQhWEGUUDDs[ZZmdCCjbnSgdoVlfWOrbnegUYNtNTFicILveIVqdiCuZY\lcC=> MnXBNVU6PTh3OEm=
ES6 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HDRmlEPTB;MD6wNVMxPiEQvF2= MlXtV2FPT0WU
A101D NYXuUFB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMEOyO|kh|ryP NXjoWodLW0GQR1XS
OCUB-M NV7OdlFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G2TmlEPTB;MD6wN|c{PyEQvF2= MXfTRW5ITVJ?
LB2518-MEL MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwMEO3OkDPxE1? M4f2cnNCVkeHUh?=
SH-4 M332fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMESzNUDPxE1? NV;URW9GW0GQR1XS
KNS-42 NF;XTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfuc|JKSzVyPUCuNFQ1PDFizszN NFPWSJpUSU6JRWK=
DSH1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPqTWM2OD1yLkC1Nlg6KM7:TR?= NWnGPHBFW0GQR1XS
NTERA-S-cl-D1 M17VdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjE[JlWUUN3ME2wMlA2Pzd{IN88US=> NInDSJRUSU6JRWK=
D-542MG MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofmTWM2OD1yLkC1PVU4KM7:TR?= M3;6cHNCVkeHUh?=
KS-1 M3Hy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHroOppKSzVyPUCuNFY1PThizszN NHPZbGhUSU6JRWK=
BL-41 NY\ibmhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LNTGlEPTB;MD6wOlk1PyEQvF2= NFLEc5NUSU6JRWK=
LXF-289 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfJN2loUUN3ME2wMlA4ODZ4IN88US=> MnznV2FPT0WU
D-247MG NIjnN4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMEeyNFkh|ryP MlLLV2FPT0WU
MMAC-SF M3vFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfYfnpKSzVyPUCuNFczPjhizszN NYfQWHNPW0GQR1XS
CP66-MEL M2TNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjTfpV6UUN3ME2wMlA4PSEQvF2= M{\SXXNCVkeHUh?=
LB771-HNC M1Sy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HieGlEPTB;MD6wPFA{PiEQvF2= NF7aTJVUSU6JRWK=
no-10 NXThPG1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwMEi5NFkh|ryP MmXjV2FPT0WU
A388 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMEmwOlUh|ryP MlnoV2FPT0WU
OPM-2 M4XxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLBeHVKSzVyPUCuNVA1PzRizszN MlzJV2FPT0WU
OVCAR-4 NUG1dFFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\Z[GlEPTB;MD6xNFk{QCEQvF2= MVLTRW5ITVJ?
HOP-62 NUnFeIdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvBNW5DUUN3ME2wMlExQTR7IN88US=> MU\TRW5ITVJ?
ML-2 NYXxWG5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fHb2lEPTB;MD6xNVgxPiEQvF2= M1r2O3NCVkeHUh?=
UACC-257 NFO3d5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT4TWM2OD1yLkGxPVI4KM7:TR?= NXzDb41kW0GQR1XS
NEC8 M{PMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjjZ3VKSzVyPUCuNVE6QTVizszN M3zLd3NCVkeHUh?=
ONS-76 M{LXfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInBbpZKSzVyPUCuNVI6OzVizszN M{\FN3NCVkeHUh?=
KE-37 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;TcZE1UUN3ME2wMlE{Ojd6IN88US=> M3LDeHNCVkeHUh?=
HT-144 MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\pZZFKSzVyPUCuNVM5QTVizszN MnnjV2FPT0WU
LB2241-RCC NFOwRZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTO[lAzUUN3ME2wMlE1OjR5IN88US=> MX\TRW5ITVJ?
TE-5 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPOTWM2OD1yLkG0Nlc5KM7:TR?= NWDBcJM4W0GQR1XS
KINGS-1 MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LNRmlEPTB;MD6xOFc6KM7:TR?= MX3TRW5ITVJ?
NCI-H69 NY\0cmN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIW3U4NKSzVyPUCuNVUyPDFizszN M{XrSHNCVkeHUh?=
CAS-1 NHWxRYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT0fZBNUUN3ME2wMlE2PDh{IN88US=> NGnUZldUSU6JRWK=
D-263MG MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LUU2lEPTB;MD6xOlAxPiEQvF2= M1nPTXNCVkeHUh?=
A253 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmW5TWM2OD1yLkG2NVI5KM7:TR?= NIPkT2VUSU6JRWK=
PF-382 MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe1eGZKSzVyPUCuNVY4ODZizszN NXiyVlhkW0GQR1XS
CESS NXX6XnJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPPTXdKSzVyPUCuNVcxPiEQvF2= MVXTRW5ITVJ?
MZ2-MEL MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMUe1OVkh|ryP NF7mO41USU6JRWK=
HEL NHO2SXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP6RZlKSzVyPUCuNVg2OTdizszN NV6yXGk5W0GQR1XS
D-392MG NWDJXpE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGC5PFFKSzVyPUCuNVkyOTVizszN M3LzTXNCVkeHUh?=
SK-LMS-1 NGLHdJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M125Z2lEPTB;MD6xPVMxOyEQvF2= M4fDRnNCVkeHUh?=
GI-ME-N NI\6[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;LOGlEPTB;MD6xPVMxPiEQvF2= MoDZV2FPT0WU
LB831-BLC M1ToOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TRRWlEPTB;MD6xPVM1KM7:TR?= NEXTdHFUSU6JRWK=
DU-4475 M{T4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMUm2OVgh|ryP NVrhPWk{W0GQR1XS
IST-SL1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f5PGlEPTB;MD6yNFA6PCEQvF2= M1vBVnNCVkeHUh?=
GAK MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrvTWM2OD1yLkKwOVM1KM7:TR?= NXfxUHhSW0GQR1XS
EW-1 NEi2d3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\WXnlJUUN3ME2wMlIyODR5IN88US=> M4HoTnNCVkeHUh?=
LAMA-84 M1XPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHW0elZKSzVyPUCuNlE5PTFizszN MVvTRW5ITVJ?
SK-UT-1 M{O2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMkKwOFkh|ryP MYLTRW5ITVJ?
VA-ES-BJ MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLTVGdKSzVyPUCuNlIzPTdizszN Mn[3V2FPT0WU
ACN M4[3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwMkK2N|gh|ryP MmfUV2FPT0WU
SK-PN-DW NGHwdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrwSYlKSzVyPUCuNlMyQSEQvF2= MYDTRW5ITVJ?
HD-MY-Z M3;hbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHUfoFoUUN3ME2wMlI{OzB|IN88US=> NI\jfWJUSU6JRWK=
LB373-MEL-D NYPz[41vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rGVWlEPTB;MD6yOFE6QCEQvF2= NX\D[Vk2W0GQR1XS
COLO-829 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\meHBKSzVyPUCuNlQzPTdizszN MYDTRW5ITVJ?
ES8 NHzwO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLSTWM2OD1yLkK0O|Y{KM7:TR?= NUniXnRMW0GQR1XS
RXF393 NXHOOGVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnlTWM2OD1yLkK1NFE2KM7:TR?= MoDNV2FPT0WU
TK10 MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH4OlVKSzVyPUCuNlU1OzVizszN NGrqeI1USU6JRWK=
LOUCY NXzCOVJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LPd2lEPTB;MD6yOVQ2PiEQvF2= NXjOe3d7W0GQR1XS
MZ7-mel MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXvTWM2OD1yLkK2N|c1KM7:TR?= MXrTRW5ITVJ?
CP67-MEL NFnUcJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu5ZY9KSzVyPUCuNlY4OyEQvF2= M4exeHNCVkeHUh?=
C2BBe1 NX;VRlZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLFcWw3UUN3ME2wMlI4QTB5IN88US=> NGTBUGdUSU6JRWK=
K052 NEXuW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDkdJZrUUN3ME2wMlI5QTlizszN NHTCNZFUSU6JRWK=
MOLT-16 M1X2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPMfFJKSzVyPUCuNlk2OjRizszN MlK0V2FPT0WU
KNS-81-FD NV\KSZVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwM{CzNlMh|ryP Ml\0V2FPT0WU
CMK M1f5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjm[IZzUUN3ME2wMlMyOTJizszN MnLwV2FPT0WU
LAN-6 M3H2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3qSGhCUUN3ME2wMlMyOyEQvF2= NVX6RY1mW0GQR1XS
KLE M4nRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HHVWlEPTB;MD6zNVMxPiEQvF2= NIDTT4ZUSU6JRWK=
NCCIT M{HrTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ntO2lEPTB;MD6zNVc5OyEQvF2= MorqV2FPT0WU
HH MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fVVmlEPTB;MD6zNlg6PyEQvF2= NFrLNXRUSU6JRWK=
TE-8 M4LaUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjWSpNtUUN3ME2wMlM1Ojd7IN88US=> NWTPOYVZW0GQR1XS
GDM-1 NETVNWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnHWYtCUUN3ME2wMlM2OTB2IN88US=> MV;TRW5ITVJ?
NCI-H747 NF7sWZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUT6RoNDUUN3ME2wMlM4OTB|IN88US=> M{PLSHNCVkeHUh?=
NCI-H1092 Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm0TWM2OD1yLkO4PFQ1KM7:TR?= NXmyU4NWW0GQR1XS
8-MG-BA M2\2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPYeHY{UUN3ME2wMlM6QDN5IN88US=> NInLOJdUSU6JRWK=
NB17 MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwNEK5O{DPxE1? NGjPclJUSU6JRWK=
LC4-1 M2PjTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHxTWM2OD1yLkSzOlA4KM7:TR?= MYnTRW5ITVJ?
TE-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfXTWM2OD1yLkS1NVE6KM7:TR?= NFHINVFUSU6JRWK=
KALS-1 NEDi[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH1TWM2OD1yLkS2OVg1KM7:TR?= M3PFdHNCVkeHUh?=
CCRF-CEM NHzoW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3S1bWlEPTB;MD60O|Y4PCEQvF2= NEHHcVFUSU6JRWK=
OS-RC-2 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fhcWlEPTB;MD60O|k4OiEQvF2= M3j0PXNCVkeHUh?=
A704 MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjib4pMUUN3ME2wMlQ5Pjl{IN88US=> NV3x[Y9NW0GQR1XS
BB49-HNC NXztZ5d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjheW9KSzVyPUCuOFkxQTZizszN MoHCV2FPT0WU
EVSA-T M4fy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fKTGlEPTB;MD60PVkyOSEQvF2= NUHZT2ZjW0GQR1XS
Mo-T MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVy2bFdrUUN3ME2wMlUyPzZ{IN88US=> NEP6RXBUSU6JRWK=
MONO-MAC-6 NH7nZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{WwNmlEPTB;MD61N|YyOSEQvF2= NIXjWXFUSU6JRWK=
BB65-RCC M2\yUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGGwbIlKSzVyPUCuOVY5OTFizszN MU\TRW5ITVJ?
NCI-H1882 NEOxPVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHLTWM2OD1yLkW5NFM3KM7:TR?= MnLMV2FPT0WU
TE-9 M4fXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHn0b5JKSzVyPUCuOlExOzNizszN NE[1TW1USU6JRWK=
NCI-H2126 M{D2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXw[m9KSzVyPUCuOlI3PjlizszN NXXhOIFTW0GQR1XS
SF268 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwNkW2OFEh|ryP MmD6V2FPT0WU
SW872 NIryUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy2elB1UUN3ME2wMlY2PzJ7IN88US=> MmryV2FPT0WU
LS-513 NHHQfHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwNk[3OVEh|ryP MVHTRW5ITVJ?
NCI-H1355 NGGxN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwNki2NVkh|ryP NV3GfnBwW0GQR1XS
BL-70 M2PZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmriTWM2OD1yLk[5N|g5KM7:TR?= MlH3V2FPT0WU
NCI-SNU-5 MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwNkm1OFUh|ryP MYfTRW5ITVJ?
SNU-C2B NVvDRoQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrkSVlKSzVyPUCuO|A4OzlizszN NIKwZVFUSU6JRWK=
GB-1 M13zc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInSVJlKSzVyPUCuO|IyOjRizszN MmnFV2FPT0WU
CTB-1 M17SXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwN{e5OVUh|ryP NIX5U4dUSU6JRWK=
Becker NFnXW3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLDTWM2OD1yLke5OlIyKM7:TR?= MU\TRW5ITVJ?
KM12 MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M361cWlEPTB;MD64OVQ3PiEQvF2= M2TjO3NCVkeHUh?=
ES7 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILJU2tKSzVyPUCuPFk3PSEQvF2= NUiycIMyW0GQR1XS
COLO-684 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rxemlEPTB;MD65NFY2QCEQvF2= MYDTRW5ITVJ?
HCC2998 NYfPSm15T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj2bnhKSzVyPUCuPVM5PTRizszN MYrTRW5ITVJ?
TE-10 M4\LTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG2bmhKSzVyPUCuPVY1OyEQvF2= NXjE[IRnW0GQR1XS
SF126 NU[5TW4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\1VmFKSzVyPUCuPVg6PzFizszN MYfTRW5ITVJ?
EKVX M3vrRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\tTWM2OD1zLkCzOFQzKM7:TR?= MWLTRW5ITVJ?
KARPAS-45 MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfJVHM6UUN3ME2xMlA1ODF4IN88US=> NGDYNFJUSU6JRWK=
KGN MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPVTWM2OD1zLkC1NFQ2KM7:TR?= NGG1VINUSU6JRWK=
ES1 M1HrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLJTWM2OD1zLkC3PVIyKM7:TR?= NGSwPZBUSU6JRWK=
L-540 NIDidopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nX[2lEPTB;MT6xNVg{QSEQvF2= NWTpXmkyW0GQR1XS
KURAMOCHI M2TIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPWdIE4UUN3ME2xMlEzOzd2IN88US=> NEfD[IZUSU6JRWK=
LU-65 NVrWSlJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zQdGlEPTB;MT6xNlc2OyEQvF2= M2jtcnNCVkeHUh?=
MFH-ino MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYflcmxVUUN3ME2xMlE4PTBzIN88US=> MY\TRW5ITVJ?
NCI-H23 NUDUVVdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmeyTWM2OD1zLkKwOFEh|ryP NHLrV4FUSU6JRWK=
IA-LM NX;3XnFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTOUGtKSzVyPUGuNlQyOTZizszN M4jIdnNCVkeHUh?=
PSN1 NIP6VVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3S4ZWlEPTB;MT6yO|AyPiEQvF2= M1HKPHNCVkeHUh?=
NCI-H719 M3\Vdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTreGVKSzVyPUGuNlc1OTFizszN MWfTRW5ITVJ?
SW684 MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFwMki2OVkh|ryP NFK4dFJUSU6JRWK=
HCE-4 NIrhblBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnq3TWM2OD1zLkOwNlIyKM7:TR?= MXnTRW5ITVJ?
EW-16 NH3lPW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{m2W2lEPTB;MT6zNVM1PyEQvF2= NVXDVFBHW0GQR1XS
NCI-H128 Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHmNnVKSzVyPUGuN|U5OTRizszN Mnr2V2FPT0WU
HC-1 MljqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorCTWM2OD1zLkO4NVch|ryP MmP3V2FPT0WU
IST-MES1 M1fDb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvXTWM2OD1zLkSwNlA5KM7:TR?= MoHBV2FPT0WU
Raji NXvNPZdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHUdmRKSzVyPUGuOFE5PSEQvF2= NVn3XnQ3W0GQR1XS
DMS-114 MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFwNES1N|kh|ryP NFHBXZRUSU6JRWK=
GI-1 Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXOTWM2OD1zLkS3NVMyKM7:TR?= M4nVVHNCVkeHUh?=
NCI-H2081 NFW4bYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X4SWlEPTB;MT61OVE6PiEQvF2= M1jKXXNCVkeHUh?=
LC-1F NHHHOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XVPGlEPTB;MT61OVE6QCEQvF2= NV23N5oxW0GQR1XS
NCI-H2227 NULycGpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTFwNkG1OlEh|ryP MnPtV2FPT0WU
D-502MG MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\nPGlEPTB;MT62O|IyOSEQvF2= NETjdllUSU6JRWK=
NCI-H2141 NGLMbnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlmyTWM2OD1zLk[3N|E4KM7:TR?= M4G5[HNCVkeHUh?=
LS-411N MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3H1dWlEPTB;MT62PVgxPyEQvF2= M4rNWnNCVkeHUh?=
SU-DHL-1 NGnLbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LKb2lEPTB;MT63NVI5OSEQvF2= MYXTRW5ITVJ?
BB30-HNC M4j0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDkZWFKSzVyPUGuO|I3QDVizszN NH70OmZUSU6JRWK=
TE-15 M2rje2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn3TWM2OD1zLkmyN|c{KM7:TR?= MY\TRW5ITVJ?
JVM-3 M3jqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTVTWdWUUN3ME2xMlk{QTB2IN88US=> NUHPOHBGW0GQR1XS
IST-SL2 M4O0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LuVWlEPTB;Mj6wNVI2OiEQvF2= NH70ZmhUSU6JRWK=
EW-18 M2S5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYOzfFdMUUN3ME2yMlAzOzN5IN88US=> MkXOV2FPT0WU
DJM-1 NITsO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojGTWM2OD1{LkCyOVUzKM7:TR?= NHLwO25USU6JRWK=
no-11 NWPHW5RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnWOFNiUUN3ME2yMlA{OTB2IN88US=> NYfLblJKW0GQR1XS
QIMR-WIL MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13YW2lEPTB;Mj6xOlc3OiEQvF2= MV3TRW5ITVJ?
MC-CAR Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX65O5JFUUN3ME2yMlIzQTVizszN NX;Nd2JSW0GQR1XS
KM-H2 NWPncJozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrFN3ZKSzVyPUKuNlkxPDNizszN NFzhVJZUSU6JRWK=
ECC12 NGThS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn71TWM2OD1{LkO3PVQh|ryP MXLTRW5ITVJ?
HCE-T NYTjV3NlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTJwNES4PFMh|ryP NHS5SIxUSU6JRWK=
MFM-223 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJwNUC4O|Eh|ryP NHn6WlRUSU6JRWK=
SW982 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTkTWM2OD1{LkWxOFgh|ryP Mmj1V2FPT0WU
KG-1 NVLIU216T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\iXWlEPTB;Mj64PFc6OSEQvF2= MX\TRW5ITVJ?
ES4 NVrhNYVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\wTWM2OD1|LkC2NVEyKM7:TR?= NU\l[G1iW0GQR1XS
SCC-3 MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTNwMUC4OFgh|ryP MUHTRW5ITVJ?
RH-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXEZVRyUUN3ME2zMlM5PzR6IN88US=> MU\TRW5ITVJ?
NCI-H748 MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjF[4xxUUN3ME2zMlQ1OjZ4IN88US=> NEPuPI5USU6JRWK=
HCC2218 NFf0WGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPuXm1KSzVyPUOuOFY6OzdizszN MkHXV2FPT0WU
MEG-01 NHTvUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkf6TWM2OD1|LkW5Olgh|ryP MXnTRW5ITVJ?
NB12 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLGVo5KSzVyPUOuOVk5QDhizszN MV\TRW5ITVJ?
SNB75 M4nw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTNwNkCxNFMh|ryP NUPremVSW0GQR1XS
KMS-12-PE NXvnTYZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTNwNke3NlMh|ryP NIPMc|dUSU6JRWK=
SKM-1 Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTNwN{GzO|Yh|ryP NVzF[lBRW0GQR1XS
COLO-320-HSR MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vFdGlEPTB;Mz63OVY{PCEQvF2= NYfJcpNOW0GQR1XS
NKM-1 NFXheWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXkTWM2OD1|Lke3N|c5KM7:TR?= NIPqW5hUSU6JRWK=
TE-6 NHTaWHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVG2NY9MUUN3ME2zMlk1PTZzIN88US=> MYDTRW5ITVJ?
D-336MG NEHwPIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;HZWlEPTB;ND6wNVE3PiEQvF2= MoDtV2FPT0WU
NCI-H1650 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLWXIhvUUN3ME20MlE2Pzl5IN88US=> NXvp[49qW0GQR1XS
ES3 M1H4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfCSYhCUUN3ME20MlMzQDJ2IN88US=> NInuR|dUSU6JRWK=
YT MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj3PGl3UUN3ME20MlM2PDJ2IN88US=> M{LLNnNCVkeHUh?=
ES5 M17iTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{e4NGlEPTB;ND60NFI2PSEQvF2= MYrTRW5ITVJ?
LB647-SCLC NEPLRoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTRwNU[zNFgh|ryP MW\TRW5ITVJ?
HAL-01 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDqO2NKSzVyPUSuOVcxOzRizszN NXPGWoRMW0GQR1XS
LP-1 NETZV5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;vb2lEPTB;ND63NlM4OSEQvF2= NXrvfIpNW0GQR1XS
BC-1 NEXES|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHuTWM2OD13LkCwOFQ4KM7:TR?= M4PQdHNCVkeHUh?=
EB-3 NUnNT297T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIGzeIZKSzVyPUWuNFMxPDFizszN MYXTRW5ITVJ?
GT3TKB M4W2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXRc3RKSzVyPUWuNVc3PjJizszN NVHGU25SW0GQR1XS
NCI-H209 NGrVSJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HKUGlEPTB;NT6xPVM2OiEQvF2= MkDjV2FPT0WU
BT-474 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPj[ZZQUUN3ME21MlI{OTB{IN88US=> NF;lTGVUSU6JRWK=
RKO NHXOfWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTVwMkO0NlIh|ryP NWTsO3RXW0GQR1XS
SIMA NYfSbGFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonSTWM2OD13LkOwO|Y2KM7:TR?= NYfmd5l6W0GQR1XS
RL Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\rSIliUUN3ME21MlM4PTRzIN88US=> NGi4[lBUSU6JRWK=
GCIY MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTVwNEeyN|Yh|ryP NYTLb2lqW0GQR1XS
Calu-6 NISzN|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnYUJNKSzVyPUWuOlIzKM7:TR?= MlT2V2FPT0WU
ALL-PO NIPoe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTVwNkO3PVUh|ryP NH7UflVUSU6JRWK=
ARH-77 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTVwNkewPFch|ryP MVTTRW5ITVJ?
A4-Fuk NHu0XJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe4eVd5UUN3ME22MlA5OTF6IN88US=> NX\2U|JXW0GQR1XS
NCI-H1581 M4DWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLLTWM2OD14LkKzPFQ6KM7:TR?= MX;TRW5ITVJ?
HUTU-80 NF\keoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFn3dpBKSzVyPU[uN|Y5QTdizszN MYrTRW5ITVJ?
TGW M{nqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTZwNEW1PVMh|ryP M3jFUnNCVkeHUh?=
SK-N-FI MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTZwNEW4OVQh|ryP M2L3O3NCVkeHUh?=
U-266 NUXWNJROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmexTWM2OD14LkWxPVI3KM7:TR?= MkHIV2FPT0WU
EM-2 NYD3dXg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTZwNkewPVkh|ryP MW\TRW5ITVJ?
NMC-G1 Mk[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7xc49xUUN3ME22MlcyQDl3IN88US=> M3vtb3NCVkeHUh?=
KASUMI-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYe1cXZtUUN3ME22Mlg1Pzh5IN88US=> MV\TRW5ITVJ?
NALM-6 NUf5R3hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTZwOE[3OVQh|ryP MWHTRW5ITVJ?
OCI-AML2 M3;jPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Tp[mlEPTB;Nz6wNFMzPiEQvF2= MXHTRW5ITVJ?
SHP-77 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:0U3pKSzVyPUeuNlI1OyEQvF2= MX7TRW5ITVJ?
NOMO-1 MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ixXWlEPTB;Nz6yOFI2PCEQvF2= NFLZT2tUSU6JRWK=
SK-N-DZ MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXWwZmQ3UUN3ME23MlcyODh7IN88US=> NXO4XnhMW0GQR1XS
LB1047-RCC NInk[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\GN2xKSzVyPUeuO|IzOzFizszN NFq5dXdUSU6JRWK=
MZ1-PC MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnKwTWM2OD15Lki2OVU5KM7:TR?= NET2UlBUSU6JRWK=
NB10 Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzNTWM2OD15Lkm5OVU3KM7:TR?= M17sPXNCVkeHUh?=
RL95-2 M{Dzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rVdmlEPTB;OD6xNFg1OiEQvF2= MonvV2FPT0WU
OMC-1 MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\6Sm9wUUN3ME24MlUzOTlzIN88US=> NWnYO48{W0GQR1XS
D-283MED NUfrcWh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7sTWM2OD16LkmxO|E6KM7:TR?= Ml;zV2FPT0WU
MC116 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HxcmlEPTB;OD65O|k1KM7:TR?= NF:1bZRUSU6JRWK=
SJSA-1 M37Bcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[ydGlEPTB;OT6wPVA6OSEQvF2= MYnTRW5ITVJ?
JiyoyeP-2003 M1XOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vqcGlEPTB;OT6yPVMyPyEQvF2= MkntV2FPT0WU
IST-MEL1 M3n0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHmRXNKSzVyPUmuO|QyQThizszN M{LIS3NCVkeHUh?=
CTV-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjkTHdKSzVyPUGwMlA6PzlizszN M3\ETnNCVkeHUh?=
NH-12 MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PQOmlEPTB;MUCuNlQ{OyEQvF2= MVTTRW5ITVJ?
CA46 NXzFcVQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFyLkO2NUDPxE1? MX3TRW5ITVJ?
NCI-SNU-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEeyTnFKSzVyPUGwMlQ6PjlizszN MUnTRW5ITVJ?
SCLC-21H MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XEOGlEPTB;MUCuOlU6PiEQvF2= M{\QZ3NCVkeHUh?=
EC-GI-10 NGW1dIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFyLkewN|Eh|ryP MkX2V2FPT0WU
SR NWW3bIRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTFzLkCxPFUh|ryP MoGxV2FPT0WU
NCI-H1648 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTFzLkC5OlUh|ryP M1f4VHNCVkeHUh?=
TGBC1TKB NHj0SFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XFTmlEPTB;MUGuOFExOiEQvF2= MWDTRW5ITVJ?
EW-11 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nEO2lEPTB;MUGuOVE5PiEQvF2= MmX0V2FPT0WU
SK-MM-2 NXPzXllpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nBdmlEPTB;MUGuPFA3OSEQvF2= M3:0ZnNCVkeHUh?=
NCI-H524 MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zubmlEPTB;MUGuPVgzOiEQvF2= Mmm2V2FPT0WU
NOS-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkG1TWM2OD1zMj6wN|Q2KM7:TR?= M4PrTnNCVkeHUh?=
AM-38 NGHXV|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTF{LkW2N|Mh|ryP NIjIZXdUSU6JRWK=
A498 M2j4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTF{LkewOlkh|ryP MoHrV2FPT0WU
KARPAS-422 NGWxcZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF{Lke0PVYh|ryP NG[2OGxUSU6JRWK=
LU-139 M13Gb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV36O4dJUUN3ME2xNk46ODJ4IN88US=> MnrJV2FPT0WU
COR-L88 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXsTWM2OD1zMj65N|gzKM7:TR?= MYfTRW5ITVJ?
K5 NHPVcXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2W3fGlEPTB;MUKuPVQ3OiEQvF2= NHrqVZlUSU6JRWK=
NB13 M1\aOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17JRmlEPTB;MUKuPVc5OyEQvF2= NXiyOGdDW0GQR1XS
MRK-nu-1 NFHHNZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTF|LkG5OUDPxE1? NYPu[FVNW0GQR1XS
MHH-NB-11 MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu4U2JKSzVyPUGzMlI6ODJizszN MknpV2FPT0WU
KU812 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPqTWM2OD1zMz62NVI1KM7:TR?= NV7N[XJpW0GQR1XS
TE-12 MoTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF|Lk[5PVQh|ryP NUPvcYtFW0GQR1XS
NCI-N87 NFjJNHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVm4d2FVUUN3ME2xN{44OzZizszN NFLnO5RUSU6JRWK=
EB2 M1K3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n6SGlEPTB;MUOuPFUxPSEQvF2= MVTTRW5ITVJ?
DB Mmn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF|Lkm4PFUh|ryP NUTmfYJrW0GQR1XS
697 M{D6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTF2LkS1NVEh|ryP NYnSOYNoW0GQR1XS
MSTO-211H NUXEcmJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3WTWM2OD1zND63OFQ5KM7:TR?= NYr0OYZ3W0GQR1XS
JVM-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PVWWlEPTB;MUSuO|c{PSEQvF2= M2nhS3NCVkeHUh?=
COLO-824 Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TpSmlEPTB;MUSuO|k6PCEQvF2= MVnTRW5ITVJ?
BC-3 M1fjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfqXlRNUUN3ME2xOU4{QThizszN NICyNXdUSU6JRWK=
BOKU MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWezS2k4UUN3ME2xOU46PjB6IN88US=> NVixWWpMW0GQR1XS
GOTO MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vMOmlEPTB;MU[uPVYyPyEQvF2= MmLPV2FPT0WU
HCC2157 M1\WPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\4TWM2OD1zNz60O|U2KM7:TR?= M{[1dHNCVkeHUh?=
LS-1034 MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LtdGlEPTB;MUeuOlgyQCEQvF2= MkX1V2FPT0WU
CAL-148 M4TaeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTOSFVKSzVyPUG3Mlk4QTZizszN M3TOZXNCVkeHUh?=
MOLT-4 NEX0emdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULVXIU2UUN3ME2xPE45OjB6IN88US=> NGK2eHJUSU6JRWK=
Daudi MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTF6LkmyN|Eh|ryP NX\HbHlqW0GQR1XS
J-RT3-T3-5 M{PldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2S1TmlEPTB;MUmuOFA3PiEQvF2= MmnPV2FPT0WU
KMOE-2 MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvoTWM2OD1zOT62OFgzKM7:TR?= NFnCUFNUSU6JRWK=
HL-60 NHTIPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJyLkG5OlUh|ryP NIjxPWFUSU6JRWK=
P31-FUJ MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYH1Tol6UUN3ME2yNE41PzV|IN88US=> NHjZS2NUSU6JRWK=
IM-9 NIW4VZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjYTWM2OD1{MD62NlI1KM7:TR?= M1\qcHNCVkeHUh?=
HDLM-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq3d49jUUN3ME2yNE45QDJzIN88US=> NXjTRnVUW0GQR1XS
NCI-H1304 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH0TWM2OD1{MT6wN|EyKM7:TR?= M3XOWHNCVkeHUh?=
NCI-H345 Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3qTWM2OD1{MT6wOlQ{KM7:TR?= MlzxV2FPT0WU
RPMI-6666 NIjaWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfLPYxKSzVyPUKxMlM3ODJizszN NG\ZO3NUSU6JRWK=
GR-ST NY\HNXpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVj3XZg6UUN3ME2yNU41OTdizszN NWHlZ4t{W0GQR1XS
CHP-126 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTJzLk[xPFEh|ryP NGDke3lUSU6JRWK=
EHEB NUnRd2NLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7oTplKSzVyPUKxMlY4OzFizszN NE\W[nlUSU6JRWK=
CPC-N NFL5do1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ThZ2lEPTB;MkSuNFIxOSEQvF2= MkDHV2FPT0WU
NB1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vlRmlEPTB;MkSuOlk{QSEQvF2= MYfTRW5ITVJ?
LS-123 NEPzU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\GWZFMUUN3ME2yOE46ODF{IN88US=> NY\zWZhFW0GQR1XS
ST486 Mo\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfK[JpKSzVyPUK1MlEyOTNizszN Ml71V2FPT0WU
NCI-H1963 M3mwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHSbllwUUN3ME2yOk4xPjJ|IN88US=> NIDmeYdUSU6JRWK=
U-87-MG M4WxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTaTWM2OD1{Nj63OlQ1KM7:TR?= MmS3V2FPT0WU
COR-L279 M1vuWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJ4Lke5NlIh|ryP MVTTRW5ITVJ?
LU-165 M{PUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTJ6LkC4OlEh|ryP MlfQV2FPT0WU
COLO-800 NV;EZ5hWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTJ6LkK5OVYh|ryP MWjTRW5ITVJ?
ETK-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnxTWM2OD1{OD6zOFQ3KM7:TR?= MX;TRW5ITVJ?
LNCaP-Clone-FGC M4SwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJ7LkmyPFEh|ryP NIrVTGZUSU6JRWK=
SIG-M5 MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4n3V2lEPTB;M{CuO|k2OiEQvF2= NFX1cWVUSU6JRWK=
NB6 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\iUYxKSzVyPUOwMlk2ODNizszN M3TXXHNCVkeHUh?=
NCI-H2107 NETyOmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWj4XnllUUN3ME2zNU4zOzN6IN88US=> MkLFV2FPT0WU
SNU-C1 NGXkbHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTNzLkOxNlYh|ryP MXvTRW5ITVJ?
JAR NUT1R3d3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj6TWM2OD1|MT6zO|k6KM7:TR?= MnzCV2FPT0WU
L-363 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3pTWM2OD1|Mj6yNVQ1KM7:TR?= MkLMV2FPT0WU
EW-24 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTN{LkO0O|Qh|ryP M4q0bXNCVkeHUh?=
NB69 M2[zemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LXVGlEPTB;M{OuOlQ2PCEQvF2= M{PBU3NCVkeHUh?=
EW-13 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTN|Lki5Olkh|ryP NF7aRYJUSU6JRWK=
Ramos-2G6-4C10 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHDTWM2OD1|ND6yPVk{KM7:TR?= Ml;MV2FPT0WU
TE-11 M{PWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjZc5VKSzVyPUO0MlQ5OjJizszN NGL1eFBUSU6JRWK=
L-428 M1;iXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTN2Lke1N|Yh|ryP M4X4[XNCVkeHUh?=
KP-N-YN MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz1eFdKSzVyPUO0MlkxPTdizszN Mn7FV2FPT0WU
CGTH-W-1 NFrmU|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPQTWM2OD1|Nj65NFQ5KM7:TR?= NF\qUlFUSU6JRWK=
K-562 M{nTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfXTWM2OD1|Nz6wPFY1KM7:TR?= M2DuWHNCVkeHUh?=
NCI-H1299 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTN6LkG2NFMh|ryP NIfQU4hUSU6JRWK=
RCC10RGB MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPVTWM2OD1|OD6yNFg{KM7:TR?= MX\TRW5ITVJ?
NCI-SNU-16 MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjuTWM2OD1|OD61OlU{KM7:TR?= MmHpV2FPT0WU
LC-2-ad MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DGSWlEPTB;M{muOFM{PyEQvF2= NVnIXmdxW0GQR1XS
MHH-PREB-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTN7LkezPFgh|ryP NUiwOGRnW0GQR1XS
NCI-H64 NEHFcoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jycGlEPTB;NECuNFk1QCEQvF2= NIrwemRUSU6JRWK=
LB996-RCC M1:3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTRyLki3NVYh|ryP MnO1V2FPT0WU
DEL Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHkfYpKUUN3ME20NU41PDB3IN88US=> NYrXO3h1W0GQR1XS
MLMA NWLPNJU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PhcmlEPTB;NEGuO|U6PSEQvF2= MVvTRW5ITVJ?
SBC-1 MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fwXmlEPTB;NEKuNVgxPiEQvF2= NVnFc|lGW0GQR1XS
MPP-89 Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zObWlEPTB;NEKuOVg4PSEQvF2= MVzTRW5ITVJ?
MV-4-11 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXjTWM2OD12Mj65NFY4KM7:TR?= MljpV2FPT0WU
EoL-1- M1fxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\VXGlEPTB;NESuNVU3QCEQvF2= MlvXV2FPT0WU
CW-2 MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TnVGlEPTB;NESuPFM1OiEQvF2= MWDTRW5ITVJ?
HT NHnB[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLSTWM2OD12NT63NFA4KM7:TR?= NYPx[3dUW0GQR1XS
SW954 NUDqPZR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrnSldpUUN3ME20O{41OTJ6IN88US=> NF7wcopUSU6JRWK=
A3-KAW NYfXfm4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTR7LkiwOlEh|ryP NYTzXplZW0GQR1XS
TC-YIK MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFL6NXFKSzVyPUWwMlA{PjNizszN MVPTRW5ITVJ?
SW962 M1LYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTV2LkizOVch|ryP Mkf2V2FPT0WU
KP-N-RT-BM-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXuclN3UUN3ME21Ok43PjN6IN88US=> M{DVSHNCVkeHUh?=
NCI-H1395 M{TlN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDyTWM2OD13OD64NVczKM7:TR?= M3XYU3NCVkeHUh?=
RPMI-8402 NH\BRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonTTWM2OD13OD65OVI3KM7:TR?= NFvsXohUSU6JRWK=
SCH MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HP[GlEPTB;NkCuPVY{QCEQvF2= M1XSbnNCVkeHUh?=
NCI-H2196 M2KzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nES2lEPTB;NkGuNlMyKM7:TR?= M3zCOXNCVkeHUh?=
LOXIMVI M1Pydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln1TWM2OD14MT64NlY3KM7:TR?= M2jiNnNCVkeHUh?=
TGBC24TKB NVK5VZpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP1bGszUUN3ME22Nk4yPDlzIN88US=> NX;KWW5QW0GQR1XS
SK-MEL-2 NVPaTXQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDrTWM2OD14Mz65PFkzKM7:TR?= NHW1NHdUSU6JRWK=
U-698-M NHjkSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjBfXBKSzVyPU[4MlU3QDdizszN MmXtV2FPT0WU
NCI-H1522 NUPuXY1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrZeVZKSzVyPU[5MlAxPDdizszN NHTBbVNUSU6JRWK=
UACC-812 NF;tOpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTZ7LkWyNFkh|ryP NWGwV2UxW0GQR1XS
MHH-CALL-2 MmCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHPTWM2OD15MD6wOkDPxE1? MYrTRW5ITVJ?
NB5 MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4O1SWlEPTB;N{CuN|Q3QCEQvF2= M1\2NXNCVkeHUh?=
KARPAS-299 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfFWmpiUUN3ME23NE41PDR5IN88US=> M{DjcHNCVkeHUh?=
NCI-H1694 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUn1UXFJUUN3ME23NU4xOzJizszN NXTJ[JE6W0GQR1XS
NCI-H82 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTdzLkm1NFch|ryP NWX0W3c4W0GQR1XS
SCC-15 NUC1[|Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn3TWM2OD15Mj6zOEDPxE1? M3PJW3NCVkeHUh?=
NCI-H1436 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1KzOmlEPTB;N{KuO|Q2PiEQvF2= MXTTRW5ITVJ?
ATN-1 M3\nSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTd2LkWwOUDPxE1? MWfTRW5ITVJ?
RPMI-8866 MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLETWM2OD15ND63OVA6KM7:TR?= MlOxV2FPT0WU
HCC1599 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;aemlEPTB;N{SuPFc{OiEQvF2= M2LxfnNCVkeHUh?=
NCI-H1155 NXW3NIxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL5V|lkUUN3ME23OE46OzZ5IN88US=> MkjkV2FPT0WU
DOHH-2 M17XOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTd2Lkm1NVQh|ryP MUjTRW5ITVJ?
SK-NEP-1 NXvYOY1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;aZ2lEPTB;N{WuNFc2PCEQvF2= NEn2SXZUSU6JRWK=
HCC1187 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVX6bpl1UUN3ME23O{43OTJ{IN88US=> M3vmU3NCVkeHUh?=
NCI-H322M NIrHTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTzPG9KSzVyPUe4MlM4ODlizszN NGPKW4RUSU6JRWK=
NCI-H526 MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfpdohKSzVyPUe4MlU5PzdizszN MlfDV2FPT0WU
NCI-H2171 MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonDTWM2OD15OT60NVM3KM7:TR?= MXzTRW5ITVJ?
COLO-668 M3vldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHGVWhKSzVyPUixMlU5QDRizszN NY\pXoNyW0GQR1XS
RS4-11 M3LmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u1b2lEPTB;OEKuNlUxPSEQvF2= MXzTRW5ITVJ?
NCI-H716 M3vRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2ewW2lEPTB;OEKuPVA4PSEQvF2= NVnMNVk6W0GQR1XS
LU-134-A MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz1TWM2OD16Mz6xN|UyKM7:TR?= NVLQVJc1W0GQR1XS
RPMI-8226 NYHPXZpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f3b2lEPTB;OESuNlExPyEQvF2= NHn1OWFUSU6JRWK=
KY821 NIntflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTlzLk[1OVEh|ryP NGfqRoVUSU6JRWK=
ECC4 NXfrVZZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[4d2s{UUN3ME25N{45OjZ7IN88US=> NEHPN25USU6JRWK=
EW-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTl2LkmwPFEh|ryP M{PsXXNCVkeHUh?=
NB7 NYLJ[nZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTl3Lke3PFYh|ryP M3PM[HNCVkeHUh?=
NCI-H720 NI\yU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTl6LkSwOlEh|ryP Mk\iV2FPT0WU
NCI-H446 M4SzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrjTWM2OD17OT63OVg5KM7:TR?= Mo\mV2FPT0WU
NCI-H889 NGrK[FBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDBSohxUUN3ME2xNFQvOjR{IN88US=> NHrMT|BUSU6JRWK=
EW-22 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTFyNj6xPUDPxE1? MoTOV2FPT0WU
BV-173 MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljwTWM2OD1zMEiuO|I5KM7:TR?= Mn3uV2FPT0WU
WSU-NHL MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\tcGlEPTB;MUC5MlY4OSEQvF2= NFTDXWlUSU6JRWK=
MN-60 NXHyWlQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTFyOT62PUDPxE1? NF3xSWJUSU6JRWK=
DG-75 MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P3SWlEPTB;MUGzMlM2OiEQvF2= MVHTRW5ITVJ?
DMS-79 MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XG[mlEPTB;MUG3MlM5OiEQvF2= M3HqS3NCVkeHUh?=
SK-MEL-1 MkjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zkTGlEPTB;MUG4MlAxQSEQvF2= M2q4dnNCVkeHUh?=
DMS-153 NUXoN2dwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjqdZZKSzVyPUGyNU44PDVizszN NXTWTVZsW0GQR1XS
NCI-H510A MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF{Nz6zNkDPxE1? MXLTRW5ITVJ?
BE-13 M3zVZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4THSGlEPTB;MUO0MlA1PCEQvF2= NHvDXndUSU6JRWK=
KP-N-YS M1T0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYT3XnhwUUN3ME2xN|kvPzN4IN88US=> MoPiV2FPT0WU
SUP-T1 M1TYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF2Mz63NFgh|ryP NXHrWI85W0GQR1XS
EW-12 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF2ND62PVkh|ryP NGjlb3BUSU6JRWK=
NB14 M2rkRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\yTWM2OD1zNEeuNFgzKM7:TR?= NUHYbodKW0GQR1XS
MDA-MB-134-VI MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\Lc456UUN3ME2xOFgvOjZ6IN88US=> MULTRW5ITVJ?
NCI-H1770 Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF3Nj6yO|kh|ryP MkLHV2FPT0WU
TUR NH\BVppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjRfY1SUUN3ME2xOlcvQDdizszN Ml\uV2FPT0WU
NCI-H1417 NVLkcGxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGj5b29KSzVyPUG4NE4{OzFizszN M{L5c3NCVkeHUh?=
IMR-5 NIXLU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX2xbnFpUUN3ME2xPFEvPTdzIN88US=> NFLHOnlUSU6JRWK=
NCI-H226 NUmxbpdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTKTWM2OD1zOEiuPFY3KM7:TR?= NVHCVVlDW0GQR1XS
NCI-H187 NV;RfZVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF7MD6wOlQh|ryP M2\US3NCVkeHUh?=
SF539 NGfNbopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXVTWM2OD1zOUKuO|I5KM7:TR?= MUHTRW5ITVJ?
TALL-1 NF\MXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHvVW5KSzVyPUG5PE4{ODRizszN M2OzRXNCVkeHUh?=
TE-441-T NWjYTVlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmS2TWM2OD1zOUmuO|M6KM7:TR?= MWLTRW5ITVJ?
REH NFm1Z5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPsN|FKSzVyPUKzOk43OjZizszN MmXGV2FPT0WU
MS-1 NHy1[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;STWM2OD1{M{muNVIyKM7:TR?= NFvjemhUSU6JRWK=
THP-1 NYPF[2ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXG1dot{UUN3ME2yOlQvPzN6IN88US=> Mnm5V2FPT0WU
NCI-H1838 MnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnS[nlTUUN3ME2yO|EvPDV4IN88US=> MoH5V2FPT0WU
P30-OHK MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrOTWM2OD1{OEOuPFQ4KM7:TR?= NYm4eYZ[W0GQR1XS
C8166 M1HYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XHeWlEPTB;M{S1MlM{QCEQvF2= MWnTRW5ITVJ?

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western Blot
Bcr-Abl; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Ac-histone H3; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Cleaved-caspase3; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Cleaved-PARP; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

ASCL1; 

PubMed: 19765735     


MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading.

CgA; 

PubMed: 19765735     


MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading.

Nrf2; 

PubMed: 23604711     


MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells.

HO-1; 

PubMed: 23604711     


MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells.

26722260 19765735 23604711
Immunofluorescence
C2GnT-M / NMIIA; 

PubMed: 22525330     


Confocal images of bC2GnT-M and NMIIA in cells treated with DMSO (D) or MG-132 (E).

AGS3 / Vimentin; 

PubMed: 20065032     


COS-7 cells were transfected with wild-type or TPR-modified AGS3 (AGS3-TPR [M1 to E470] or AGS3-GPR [E470 to S650]) in pEGFP-N1. Thirty-six hours after transfection, cells were incubated with MG 132 (10 μM) for 12 h, and then the cells were processed for immunofluorescence microscopy. The images presented are representative of 2 to 10 separate transfections.

Bak; 

PubMed: 20557369     


Proteasome inhibitor induces Bak activation. Cells were treated with either vehicle or MG-132 at 10 µmol/L for 12 hours and were subjected to Bak immunofluorescence study using antiserum specific for the N terminus of Bak. Upon Bak activation, this epitope is no longer masked within the protein and becomes available for antibody binding upon Bak conformational change.

22525330 20065032 20557369
Growth inhibition assay
Apoptosis assay; 

PubMed: 20557369     


LX-2 cells were incubated for 24 hours in the presence of increasing concentrations of MG-132 (0, 2.5, 5, 10 µmol/L) and in the presence of the pan-caspase inhibitor QVD at 5 µmol/L for 24 hours. MG-132 and QVD were prepared in DMSO as a vehicle. All data were expressed as mean ± standard error from three individual experiments. * p < 0.01 (10 µmol/L MG-132 treated cells vs. 10 µmol/L MG-132 plus QVD treated cells)

Cell viability; 

PubMed: 26137056     


The proteasome inhibitor MG-132 significantly decreased the cell viability in EC9706 cells in a dose- and time-dependent manner.

cell proliferation ; 

PubMed: 19765735     


MG-132 significantly inhibits growth of carcinoid tumor cells in vitro. Pulmonary (NCI-H727) and GI (BON) carcinoid tumor cells were treated with MG-132 at the indicated concentrations (0 to 4µM) for up to 6 days and cell viability was measured every 2 days with the MTT assay (P<0.001). The results show that MG-132 leads to the suppression cellular proliferation in NCI-H727 (A) and BON (B) cells. (OD, optical density)

20557369 26137056 19765735
ELISA
IL-8; 

PubMed: 11160671     


ELISA of IL-8 from supernatant of eTat cells. eTat cells were blocked with Hu (2 mM) and released. MG-132 (50 μM) was added at the time of release. The supernatant was collected at 3 h postrelease and analyzed for IL-8 protein using ELISA. The result shown is representative of three independent experiments ± standard deviation. 

IL-1beta; 

PubMed: 22606244     


LPS-primed WT BMDM were incubated in control medium or medium containing 10 ng/ml ricin or 25 µg/ml cycloheximide for 4 h. MG-132 (30 µM) or Bortezimib (0.5 µM) was included as indicated. Secreted IL-1ß was measured by ELISA in triplicate wells.

11160671 22606244
体内試験 Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Measurement of inhibitory activities of MG-132 against 20S proteasome:

The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.
細胞試験:

[3]

+ 展開
  • 細胞株: KIM-2, HC11, and ES
  • 濃度: Dissolved in DMSO, final concentrations ~25 μM
  • 反応時間: 24 and 48 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.


    (参考用のみ)
動物試験:

[7]

+ 展開
  • 動物モデル: Male mdx (C57BL/10ScSn DMD mdx) mice
  • 製剤: Dissolved in DMSO, and diluted in PBS
  • 投薬量: ~10 μg/kg/day
  • 投与方法: Injection
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 90 mg/mL (189.22 mM)
Ethanol 25 mg/mL (52.56 mM)
Water Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
4% DMSO+30% PEG 300+20% propylene glycol+ddH2O
混合させたのち直ちに使用することを推奨します。
2mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 475.62
化学式

C26H41N3O5

CAS No. 133407-82-6
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I want to know whether it contains EDTA or other chelating agent in this product(S2619)?

  • 回答:

    Our S2619 MG-132 doesn't contain EDTA or other chelating agent.

Proteasomeシグナル伝達経路

Proteasome Inhibitors with Unique Features

相関Proteasome製品

Tags: MG-132を買う | MG-132 ic50 | MG-132供給者 | MG-132を購入する | MG-132費用 | MG-132生産者 | オーダーMG-132 | MG-132化学構造 | MG-132分子量 | MG-132代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID